Plozasiran is an investigational RNA interference therapeutic designed to reduce the production of apolipoprotein C-III, a protein produced in the liver that regulates triglyceride metabolism in the blood.
Donidalorsen delivered significant and sustained reductions in HAE attacks, with high levels of disease control and improvement in quality of life measures with monthly or every two-month dosing;.
Iterum: FDA Accepts Resubmission Of NDA For Oral Sulopenem rttnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from rttnews.com Daily Mail and Mail on Sunday newspapers.
Iterum Therapeutics plc Receives FDA Acceptance of Resubmission of NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.